Merck Healthcare announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals.
Merck Healthcare today announced a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui). The partnership includes an exclusive license worldwide (ex-China) to develop, manufacture and commercialize Hengrui’s next-generation potent and selective PARP1 (poly (ADP-ribose) polymerase 1) trapping inhibitor HRS-1167.…